|
08 Jul 2019 |
Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients
|
|
08 Jul 2019 |
New data show nonacog beta pegol (N9-GP) is effective and well tolerated for the prevention and treatment of bleeding in children with haemophilia B
|
|
08 Jul 2019 |
Interim Data Evaluating Elocta® for Immune Tolerance Induction in People With Inhibitors and Severe Haemophilia A Shared at ISTH 2019
|
|
08 Jul 2019 |
Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A
|
|
07 Jul 2019 |
Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019
|
|
04 Jul 2019 |
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
|
|
03 Jul 2019 |
Orion Biotechnology's CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis
|
|
01 Jul 2019 |
La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock
|
|
01 Jul 2019 |
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
|
|
27 Jun 2019 |
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery
|
|
27 Jun 2019 |
ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
|
|
26 Jun 2019 |
Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
|
|
25 Jun 2019 |
Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease
|
|
24 Jun 2019 |
Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
|
|
22 Jun 2019 |
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
|
|
22 Jun 2019 |
FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
|
|
21 Jun 2019 |
Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU
|
|
21 Jun 2019 |
Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
|
|
21 Jun 2019 |
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
|
|
21 Jun 2019 |
Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
|
|
20 Jun 2019 |
Arch Biopartners Announces Start of Phase I Human Trial for Metablok
|
|
19 Jun 2019 |
Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream
|
|
19 Jun 2019 |
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
|
|
18 Jun 2019 |
Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
|
|
18 Jun 2019 |
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
|
